| Literature DB >> 34796141 |
Jong Man Kim1, Jinsoo Rhu1, Sang Yun Ha2, Gyu-Seong Choi1, Choon Hyuck David Kwon3, Gaabsoo Kim4, Jae-Won Joh1.
Abstract
PURPOSE: Little is known about liver resection (LR) in hepatocellular carcinoma (HCC) patients older than 75 years of age. This study aimed to compare the postoperative and long-term outcomes of hepatectomy in this patient population according to operation period.Entities:
Keywords: Aged; Hepatectomy; Minimally invasive surgical procedures; Recurrence; Survival
Year: 2021 PMID: 34796141 PMCID: PMC8564081 DOI: 10.4174/astr.2021.101.5.257
Source DB: PubMed Journal: Ann Surg Treat Res ISSN: 2288-6575 Impact factor: 1.859
Baseline characteristics
Values are presented as number only, median (range), or number (%).
NBNC, non B non C; INR, international normalized ratio; AFP, alpha-fetoprotein; PIVKA-II, proteins induced by vitamin K absence or antagonist-II; ICG-R15, indocyanine green at 15 minutes; ALBI, albumin-bilirubin; APRI, AST to platelet ratio index.
Perioperative and pathological characteristics
Values are presented as number (%), median (range), or number only.
ASA, American Society of Anesthesiologists; PS, physical status; PVTT, portal vein tumor thrombosis.
Hepatocellular carcinoma (HCC) recurrence
Values are presented as number (%), number only, or median (range).
HCC, hepatocellular carcinoma; AFP, alpha-fetoprotein; PIVKA-II, proteins induced by vitamin K absence or antagonist-II; TACE, transarterial chemoembolization; RFA, radiofrequency ablation.
Fig. 1(A) Disease-free survival (DFS) and (B) overall survival (OS) between group 1 and group 2. Group 1, the patients who underwent liver resection before 2016 (n = 68); group 2, the patients who underwent liver resection during or after 2016 (n = 62).
Risk factors for hepatocellular carcinoma (HCC) recurrence and mortality in multivariate analyses
OR, odds ratio; CI, confidence interval; APRI, AST to platelet ratio index; PVTT, portal vein tumor thrombosis; PIVKA-II, proteins induced by vitamin K absence or antagonist-II; NA, not applicable.
Group 1, the patients who underwent liver resection before 2016 (n = 68); group 2, the patients who underwent liver resection during or after 2016 (n = 62).